OBJECTIVE: To evaluate the benefit of niacin in addition to statin therapy on plaque regression among older individuals with established atherosclerosis. DESIGN: Randomised, controlled, double-blind clinical trial. SETTING:University outpatient center. PATIENTS: 145 patients older than 65 years, half of them older than 75 years of age, with established atherosclerosis were enrolled. INTERVENTIONS: Participants received either extended release niacin (1500 mg daily) or placebo in addition to statin therapy to reach their National Cholesterol Education Program-defined low density lipoprotein (LDL) cholesterol target. MAIN OUTCOME MEASURES: The primary endpoint was reduction in the wall volume of the internal carotid artery (ICA) measured by MRI. RESULTS: After 18 months, high density lipoprotein cholesterol was higher with statins plus niacin compared with statins alone (1.6 ± 0.4 vs 1.4 ± 0.4 mmol/L p<0.001). Both groups had significant decreases in the main outcome measure of ICA wall volume, which regressed at 0.5%/month (SEM 0.2, p=0.004) in the statins plus placebo group and at 0.7%/month in the statins plus niacin group (SEM 0.2, p<0.001). There was no difference in the rate of regression between groups (p=0.49). CONCLUSIONS: Treatment with statin therapy to presently recommended LDL levels, with or without niacin, resulted in significant atherosclerosis reduction.
RCT Entities:
OBJECTIVE: To evaluate the benefit of niacin in addition to statin therapy on plaque regression among older individuals with established atherosclerosis. DESIGN: Randomised, controlled, double-blind clinical trial. SETTING: University outpatient center. PATIENTS: 145 patients older than 65 years, half of them older than 75 years of age, with established atherosclerosis were enrolled. INTERVENTIONS:Participants received either extended release niacin (1500 mg daily) or placebo in addition to statin therapy to reach their National Cholesterol Education Program-defined low density lipoprotein (LDL) cholesterol target. MAIN OUTCOME MEASURES: The primary endpoint was reduction in the wall volume of the internal carotid artery (ICA) measured by MRI. RESULTS: After 18 months, high density lipoproteincholesterol was higher with statins plus niacin compared with statins alone (1.6 ± 0.4 vs 1.4 ± 0.4 mmol/L p<0.001). Both groups had significant decreases in the main outcome measure of ICA wall volume, which regressed at 0.5%/month (SEM 0.2, p=0.004) in the statins plus placebo group and at 0.7%/month in the statins plus niacin group (SEM 0.2, p<0.001). There was no difference in the rate of regression between groups (p=0.49). CONCLUSIONS: Treatment with statin therapy to presently recommended LDL levels, with or without niacin, resulted in significant atherosclerosis reduction.
Authors: João A C Lima; Milind Y Desai; Henning Steen; William P Warren; Sandeep Gautam; Shenghan Lai Journal: Circulation Date: 2004-10-11 Impact factor: 29.690
Authors: Donna M Zulman; Jeremy B Sussman; Xisui Chen; Christine T Cigolle; Caroline S Blaum; Rodney A Hayward Journal: J Gen Intern Med Date: 2011-02-01 Impact factor: 5.128
Authors: Bruce A Wasserman; William I Smith; Hugh H Trout; Richard O Cannon; Robert S Balaban; Andrew E Arai Journal: Radiology Date: 2002-05 Impact factor: 11.105
Authors: William E Boden; Jeffrey L Probstfield; Todd Anderson; Bernard R Chaitman; Patrice Desvignes-Nickens; Kent Koprowicz; Ruth McBride; Koon Teo; William Weintraub Journal: N Engl J Med Date: 2011-11-15 Impact factor: 91.245
Authors: Erin D Michos; Christopher T Sibley; Jefferson T Baer; Michael J Blaha; Roger S Blumenthal Journal: J Am Coll Cardiol Date: 2012-04-18 Impact factor: 24.094
Authors: Joseph F Polak; Michael J Pencina; Karol M Pencina; Christopher J O'Donnell; Philip A Wolf; Ralph B D'Agostino Journal: N Engl J Med Date: 2011-07-21 Impact factor: 91.245
Authors: James H Stein; Pamela S Douglas; Sathanur R Srinivasan; M Gene Bond; Rong Tang; Shengxu Li; Wei Chen; Gerald S Berenson Journal: Stroke Date: 2004-10-28 Impact factor: 7.914
Authors: Sarah Lewington; Gary Whitlock; Robert Clarke; Paul Sherliker; Jonathan Emberson; Jim Halsey; Nawab Qizilbash; Richard Peto; Rory Collins Journal: Lancet Date: 2007-12-01 Impact factor: 79.321
Authors: Stefan Schandelmaier; Matthias Briel; Ramon Saccilotto; Kelechi K Olu; Armon Arpagaus; Lars G Hemkens; Alain J Nordmann Journal: Cochrane Database Syst Rev Date: 2017-06-14
Authors: Christopher T Sibley; Tyra Estwick; Anna Zavodni; Chiung-Yu Huang; Alan C Kwan; Benjamin P Soule; Debra A Long Priel; Alan T Remaley; Amanda K Rudman Spergel; Evrim B Turkbey; Douglas B Kuhns; Steven M Holland; Harry L Malech; Kol A Zarember; David A Bluemke; John I Gallin Journal: Circulation Date: 2014-09-19 Impact factor: 29.690
Authors: Jason M Tarkin; Marc R Dweck; Nicholas R Evans; Richard A P Takx; Adam J Brown; Ahmed Tawakol; Zahi A Fayad; James H F Rudd Journal: Circ Res Date: 2016-02-19 Impact factor: 17.367
Authors: Veit Sandfort; Shenghan Lai; Mark A Ahlman; Marissa Mallek; Songtao Liu; Christopher T Sibley; Evrim B Turkbey; João A C Lima; David A Bluemke Journal: J Am Heart Assoc Date: 2016-07-13 Impact factor: 5.501